Arrowhead Pharmaceuticals (ARWR) Leases: 2010-2025
Historic Leases for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to $43.9 million.
- Arrowhead Pharmaceuticals' Leases fell 3.01% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 3.01%. This contributed to the annual value of $43.9 million for FY2025, which is 3.01% down from last year.
- Per Arrowhead Pharmaceuticals' latest filing, its Leases stood at $43.9 million for Q3 2025, which was down 0.25% from $44.0 million recorded in Q2 2025.
- Over the past 5 years, Arrowhead Pharmaceuticals' Leases peaked at $96.3 million during Q2 2023, and registered a low of $33.1 million during Q1 2021.
- Its 3-year average for Leases is $49.1 million, with a median of $44.6 million in 2024.
- Per our database at Business Quant, Arrowhead Pharmaceuticals' Leases spiked by 72.54% in 2021 and then tumbled by 53.98% in 2024.
- Arrowhead Pharmaceuticals' Leases (Quarterly) stood at $42.0 million in 2021, then increased by 0.10% to $42.0 million in 2022, then increased by 6.88% to $44.9 million in 2023, then declined by 0.08% to $44.9 million in 2024, then declined by 3.01% to $43.9 million in 2025.
- Its Leases was $43.9 million in Q3 2025, compared to $44.0 million in Q2 2025 and $44.5 million in Q1 2025.